This morning, Peregrine Pharmaceuticals (NASDAQ: PPHM) released additional details regarding its revised analysis of bavituximab in non-small cell lung cancer. Today's release comes less than a week after investors totally misinterpreted clinical data on the drug used in pancreatic cancer, initially bidding up shares before a sharp sell-off later in the day. As Brenton Flynn outlines in the video below, this time around the investor reaction has been much more rational.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Investors aren't too excited about this secondary data analysis
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Celgene
CELG
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Genmab Stock Was Marching Higher Today
Why Pfizer Stock Just Popped
Why Nuvation Bio Stock Is Skyrocketing Today
Could This Beaten-Down Stock Help You Become a Millionaire?
Why This Beaten-Down GLP-1 Stock Could Be a Steal
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.